These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34530257)

  • 21. Prognostic role of PD-L1 expression in head and neck squamous cell carcinoma: An institutional experience from India.
    Kala PS; Thapliyal N; Pant B; Sharma N; Pandey HS
    Pathol Res Pract; 2024 Feb; 254():155133. PubMed ID: 38306860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
    Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
    Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations.
    Bill R; Faquin WC; Pai SI
    Head Neck Pathol; 2023 Dec; 17(4):969-975. PubMed ID: 37930471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
    Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
    Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
    Haddad RI; Seiwert TY; Chow LQM; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Albright A; Mogg R; Ayers M; Huang L; Lunceford J; Cristescu R; Cheng J; Mehra R
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of choice of materials and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell carcinoma.
    De Meulenaere A; Vermassen T; Creytens D; Aspeslagh S; Deron P; Duprez F; Rottey S; Van Dorpe JA; Ferdinande L
    Histopathology; 2018 Sep; 73(3):500-509. PubMed ID: 29768723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.
    Karabajakian A; Bouaoud J; Michon L; Kamal M; Crozes C; Zrounba P; Auclair-Perossier J; Gadot N; Attignon V; Le Tourneau C; Benzerdjeb N; Fayette J; Saintigny P
    Oral Oncol; 2021 Aug; 119():105368. PubMed ID: 34111704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of programmed death-ligand 1 protein expression between primary tumors and lymph node metastatic lesions in oral squamous cell carcinoma].
    Xia RH; Hu YH; Zhang CY; Xu SM; Li J
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2022 Nov; 57(11):1113-1118. PubMed ID: 36379889
    [No Abstract]   [Full Text] [Related]  

  • 29. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
    Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
    Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma.
    Rasmussen JH; Lelkaitis G; Håkansson K; Vogelius IR; Johannesen HH; Fischer BM; Bentzen SM; Specht L; Kristensen CA; von Buchwald C; Wessel I; Friborg J
    Br J Cancer; 2019 May; 120(10):1003-1006. PubMed ID: 30967647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
    Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
    Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 expression in fine-needle aspiration cell blocks of head and neck squamous-cell carcinoma and its cytohistological concordance.
    Lou SSK; Ruff H; MacDonald S; Smith SM; Cheung CC
    Diagn Cytopathol; 2024 Mar; 52(3):163-170. PubMed ID: 38095142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells.
    Eichberger J; Schulz D; Pscheidl K; Fiedler M; Reichert TE; Bauer RJ; Ettl T
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
    Okada S; Itoh K; Ishihara S; Shimada J; Kato D; Tsunezuka H; Miyata N; Hirano S; Teramukai S; Inoue M
    Surg Oncol; 2018 Jun; 27(2):259-265. PubMed ID: 29937180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune gene expression in head and neck squamous cell carcinoma patients.
    Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
    Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 expression in head and neck squamous cell carcinoma and its clinical significance: A prospective observational study from a tertiary care centre.
    Kilaru S; Panda SS; Moharana L; Mohapatra D; Mohapatra SSG; Panda A; Kolluri S; Devaraj S; Kabi A; Das B; Biswas G
    J Cancer Res Ther; 2024 Jan; 20(1):46-51. PubMed ID: 38554297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.